Quantitative Bone Scintigraphy in Patients with Prostatic Carcinoma Treated with LH-RH Analogues

Scandinavian Journal of Urology and Nephrology

Volumn 30, Issue 1, 1996, Pages 29-32

  Sundkvist, G M G ^a,b   Bjork T ^a   Kjellstrom H ^a   Lilja, B ^a  

^a LUND UNIVERSITY   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

Author keywords

Luteinizing hormone releasing hormone analogues; Prostate specific antigen; Prostatic carcinoma; Quantitative bone scintigraphy

Indexed keywords

GONADORELIN; PROSTATE SPECIFIC ANTIGEN; GONADORELIN DERIVATIVE; MEDRONATE TECHNETIUM TC 99M;

AGED; ARTICLE; BLOOD; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; SCINTISCANNING; SPINE; WHOLE BODY COUNTING; ADULT; BONE SCINTISCANNING; CLINICAL ARTICLE; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA;

AGED; AGED, 80 AND OVER; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SPINE; WHOLE-BODY COUNTING;

EID: 0029666398     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365599609182345     Document Type: Article

References (17)

1. Brawn PN, Speights VO. The dedifferentiation of metastatic prostate carcinoma. Br J Cancer 1989; 59: 85-88.
2. Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-318.
3. Crawford ED. Hormonal therapy of prostatic carcinoma. Defining the challenge. Cancer 1990; 66: 1035-1038.
4. Grayhack JT, Keeler TC, Kozlowski JM. Carcinoma of the prostate. Hormonal therapy. Cancer 1987; 60: 589-601.
5. Hetherington JW, Siddall JK, Cooper EH. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer. Eur Urol 1988; 14: 1-5.
6. Huggins C, Hodges CV. Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
7. Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer 1993; 72: 3788-3792.
8. Smith Jr JA. New methods of endocrine management of prostatic cancer. J Urol 1987; 137: 1-10.
9. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, Iowa: Iowa State University Press 1980.
10. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990; 66: 1017-1021.
11. Sundkvist GMG, Ahlgren L, Lilja B, Mattsson S, Abrahamsson PA, Wadström LB. Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchiectomy. Eur J Nucl Med 1988; 14: 203-206.
12. Sundkvist GMG, Ahlgren L, Lilja B, Mattsson S, Abrahamsson PA. Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy. Eur J Nucl Med 1990; 16: 671-676.
13. 99mTc-MDP bone scintigraphy in patients with prostatic carcinoma. Acta Oncol 1991; 30: 635-639.
14. Sundkvist GMG. Quantitative bone scintigraphy. A study in patients with prostatic carcinoma. Thesis, Malmö. 1991.
15. 99mTc-methylene diphosphonate in patients with prostatic carcinoma. Nucl Med 1992; 31: 178-181.
16. Sundkvist GMG, Ahlgren L, Lilja B, Mattsson S. Quantitative bone scintigraphy in prostatic carcinoma - long-term response to treatment. Nucl Med 1993; 32: 231-235.
17. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-163.